StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.72−0.24 (-3.02%)

Close on Nov 19, 2026Market cap $1.27BP/E –Yield –

Novavax operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Novavax's operating income for the twelve months ending Jun 30, 2026 was -$234.12M, down 166.6% year over year. For fiscal 2025 it was $452.80M. The highest annual figure on record is $452.80M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$452.80M–
FY2024Dec 31, 2024-$248.93M–
FY2023Dec 31, 2023-$566.51M–
FY2022Dec 31, 2022-$644.74M–
FY2021Dec 31, 2021-$1.69B–
FY2020Dec 31, 2020-$416.72M–
FY2019Dec 31, 2019-$120.58M–
FY2018Dec 31, 2018-$173.92M–
FY2017Dec 31, 2017-$171.71M–
FY2016Dec 31, 2016-$269.11M–
FY2015Dec 31, 2015-$157.24M–
FY2014Dec 31, 2014-$83.69M–
FY2013Dec 31, 2013-$52.43M–
FY2012Dec 31, 2012-$29.67M–
FY2011Dec 31, 2011-$21.58M–
FY2010Dec 31, 2010-$38.49M–
FY2009Dec 31, 2009-$37.38M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$54.91M-154.3%
Q1 FY2026Mar 31, 2026-$15.43M-103.0%
Q4 FY2025Dec 31, 2025$14.23M–
Q3 FY2025Sep 30, 2025-$178.02M–
Q2 FY2025Jun 30, 2025$101.07M-37.2%
Q1 FY2025Mar 31, 2025$515.51M–
Q4 FY2024Dec 31, 2024-$131.08M–
Q3 FY2024Sep 30, 2024-$134.02M–
Q2 FY2024Jun 30, 2024$161.00M+190.3%
Q1 FY2024Mar 31, 2024-$144.83M–
Q4 FY2023Dec 31, 2023-$183.57M–
Q3 FY2023Sep 30, 2023-$125.63M–
Q2 FY2023Jun 30, 2023$55.46M–
Q1 FY2023Mar 31, 2023-$312.77M-249.4%
Q4 FY2022Dec 31, 2022-$243.88M–
Q3 FY2022Sep 30, 2022-$127.19M–
Q2 FY2022Jun 30, 2022-$482.96M–
Q1 FY2022Mar 31, 2022$209.29M–
Q4 FY2021Dec 31, 2021-$824.97M–
Q3 FY2021Sep 30, 2021-$307.14M–
Q2 FY2021Jun 30, 2021-$345.83M–
Q1 FY2021Mar 31, 2021-$208.63M–
Q4 FY2020Dec 31, 2020-$182.85M–
Q3 FY2020Sep 30, 2020-$193.94M–
Q2 FY2020Jun 30, 2020-$17.03M–
Q1 FY2020Mar 31, 2020-$22.90M–
Q4 FY2019Dec 31, 2019-$28.71M–
Q3 FY2019Sep 30, 2019-$14.99M–
Q2 FY2019Jun 30, 2019-$36.67M–
Q1 FY2019Mar 31, 2019-$40.22M–
Q4 FY2018Dec 31, 2018-$46.51M–
Q3 FY2018Sep 30, 2018-$41.90M–
Q2 FY2018Jun 30, 2018-$41.99M–
Q1 FY2018Mar 31, 2018-$43.51M–
Q4 FY2017Dec 31, 2017-$47.78M–
Q3 FY2017Sep 30, 2017-$41.63M–
Q2 FY2017Jun 30, 2017-$41.47M–
Q1 FY2017Mar 31, 2017-$40.83M–
Q4 FY2016Dec 31, 2016-$54.05M–
Q3 FY2016Sep 30, 2016-$63.31M–

More Novavax figures

See a number that looks wrong?